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ABSTRACT 
 
DNA methylation changes during aging, but it remains unclear whether the effect of DNA methylation on 
lung cancer survival varies with age. Such an effect could decrease prediction accuracy and treatment 
efficacy. We performed a methylation–age interaction analysis using 1,230 early-stage lung adenocarcinoma 
patients from five cohorts. A Cox proportional hazards model was used to investigate lung adenocarcinoma 
and squamous cell carcinoma patients for methylation–age interactions, which were further confirmed in a 
validation phase. We identified one adenocarcinoma-specific CpG probe, cg14326354PRODH, with effects 
significantly modified by age (HRinteraction = 0.989; 95% CI: 0.986–0.994; P = 9.18×10–7). The effect of low 
methylation was reversed for young and elderly patients categorized by the boundary of 95% CI standard 
(HRyoung = 2.44; 95% CI: 1.26–4.72; P = 8.34×10-3; HRelderly = 0.58; 95% CI: 0.42–0.82; P = 1.67×10-3). 
Moreover, there was an antagonistic interaction between low cg14326354PRODH methylation and elderly age 
(HRinteraction = 0.21; 95% CI: 0.11–0.40; P = 2.20×10−6). In summary, low methylation of cg14326354PRODH 
might benefit survival of elderly lung adenocarcinoma patients, providing new insight to age-specific 




Population aging has resulted in a rapid increase in lung 
cancer cases as well as corresponding surgeries among 
elderly patients [1]. Indeed, the median age at diagnosis 
of lung cancer is 70 years old [2]. Further, lung cancer 
leads as a cause of cancer deaths among men ≥40 years 
old and women ≥60 years old [3]. 
 
Progression of lung cancer is, in part, due to accumulation 
of genomic instability as well as age-related declines in 
system integrity and function [4]. Thus, even for 
individuals exposed to similar levels of risk factors, lung 
cancer severity can vary as a function of individual 
differences in aging. Therefore, compared to predictive 
guidance for the overall population, effective predictive 
guidance for age-specific populations, especially elderly 
patients, is needed to better guide postoperative treatment 
and improve survival. Developing such guidance 
necessitates identifying exclusive prognostic indicators of 
lung cancer for the elderly.  
 
Epigenetic mechanisms represent the molecular 
interface mediating gene–environment interactions 
throughout the lifecycle [5]. DNA methylation, a 
reversible epigenetic modification, correlates with 
tumor prognosis in almost all cancers including non-
small cell lung cancer (NSCLC) [6–9]. DNA 
methylation events may potentially be cancer bio-
markers as well as therapeutic targets to improve cancer 
treatment [10].  
 
Alterations to DNA methylation often occur during 
aging [11]. One of these alterations, known as 
“epigenetic drift”, may further contribute to 
tumorigenesis in the elderly [12]. Changes in DNA 
methylation also can contribute to senescence [13]. 
However, it remains largely unclear whether alterations 
of methylation patterns resulting from aging, 
accumulating environmental exposures throughout life 
[14], and other events also have varied effects on cancer 
survival during aging. Such phenomena may further 
explain the increased alteration of cancer mortality risk 
with age and may increase the effectiveness of cancer 
prediction and treatment. 
 
We hypothesized that the methylation effect on cancer 
survival changes during aging. Thus, identifying age-
specific signatures will be critical for prognosis 
prediction, underpinning potential preventative 
strategies, and improving survival for elderly patients. 
However, most epigenome-wide association studies are 
designed to identify main effects of DNA methylation 
and fail to provide knowledge about changes in 
epigenetic effects during aging. Thus, we performed an 
epigenome-wide methylation–age interaction analysis to 
identify age-specific, prognosis-associated epigenetic 
biomarkers using NSCLC patients from four cohorts, 
along with an independent population from The Cancer 




After quality control (QC) procedures, 1,230 lung 
adenocarcinoma (LUAD) and lung squamous cell 
carcinoma (LUSC) patients with 311,891 CpG probes 
remained for subsequent association analysis. There 
were 613 (NLUAD = 492; NLUSC = 121) patients in the 
discovery phase, and 617 (NLUAD = 332; NLUSC = 285) 
patients in the validation phase. The average age was 
66.4 and 66.5 years for patients in the discovery and 
validation phases, respectively. Most NSCLC patients 
were in stage I (77.5% in discovery; 63.7% in 
validation) (Supplementary Table 1). 
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We only observed two significant methylation–age 
interactions for LUAD patients in the discovery phase 
(Figure 1, Supplementary Figure 1, Supplementary 
Table 2), and none for LUSC patients. Results of the 
epigenome-wide association study are shown in 
Supplementary Materials 1 and 2. In the validation 
phase, only one LUAD-specific CpG probe, located in 
proline dehydrogenase 1 (PRODH) (Supplementary 
Table 3), remained significant.  
 
Low methylation of cg14326354PRODH interacted with 
age to affect survival of patients (discovery phase: 
hazard ratio (HR)interaction = 0.982; 95% CI: 0.976–
0.989; P = 1.11×10–7; validation phase: HRinteraction = 
0.981; 95% CI: 0.966–0.997; P = 0.0202; combined 
data: HRinteraction = 0.989; 95% CI: 0.986–0.994; P = 
9.18×10–7). Further, the robustly significant interaction 
effect was confirmed in sensitivity analysis by 
removing outliers in methylation data (Supplementary 
Table 4). When using leave-one-out method for 
validation, the interaction remained significant 
(Supplementary Figure 2). Moreover, meta-analysis 
also exhibited significant (HRinteraction = 0.983; 95% CI: 
0.976–0.990; P = 3.95×10–6) and homogenous 
(PHeterogeneity = 0.97) interaction effects across five 
cohorts (Supplementary Figure 3). Based on stratified 
analysis by smoking status, sex, clinical stage, and 
study cohort, there was no significant heterogeneity of 
interaction effect between subgroups of any of these 
covariates (Supplementary Table 5).  
With increased age, there was an increased protective 
effect for low methylation of cg14326354PRODH on 
LUAD survival (Figure 2A, Supplementary Figure 4). 
Thus, age was a modifier of the association between 
cg14326354PRODH and survival. To better understand the 
interaction between DNA methylation and age, patients 
were categorized into young and elderly groups based on 
the boundary of 95% CI (BoCI) of HR (<57 vs >65 years 
in Figure 2A) or the United Nations (UN) standard (≤65 
vs >65 years). The BoCI standard provided stable results 
in both phases as well as combined data (Supplementary 
Table 6), with varied effects of cg14326354PRODH 
methylation across different age groups. Low methy-
lation of cg14326354PRODH showed a risk effect on 
survival for young patients (HRBoCI = 1.20; 95% CI: 
1.03–1.40; P = 1.97×10–2; HRUN = 1.10; 95% CI: 0.99–
1.22; P = 8.71×10–2) but benefited survival of elderly 
LUAD patients (HRBoCI = 0.81; 95% CI: 0.75–0.88; P = 
5.38×10–7; HRUN = 0.81; 95% CI: 0.75–0.88; P = 
5.38×10–7) (Figure 2B). Kaplan-Meier curves also 
confirmed reversed effect patterns across age groups 
based on BoCI standard (HRyoung = 2.44; 95% CI: 1.26–
4.72; P = 8.34×10-3; HRelderly = 0.58; 95% CI: 0.42–0.82; 
P = 1.67×10-3), with methylation groups defined by 
median values. There was significant heterogeneity of the 
low cg14326354PRODH methylation effect between young 
and elderly patients (I2 = 93.03%, Q = 14.35, P = 
1.52×10-4) (Figure 2C). These results indicated that 
elderly LUAD patients had better survival with lower 




Figure 1. Flow chart of study design and statistical analyses. 
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In addition, we evaluated the joint effect of 
cg14326354PRODH methylation level (low vs high) and 
age (elderly vs young) on LUAD survival (Table 1). 
The group with the best survival (young patients with 
high methylation) was used as the reference to evaluate 
effects of low methylation, elderly age, and their 
interaction. The main effect of low cg14326354PRODH 
methylation was HR = 2.84 (95% CI: 1.59–5.08, P = 
4.35×10−4), and the main effect of elderly age was HR = 
3.18 (95% CI: 1.85–5.46, P = 2.64×10−5). However, the 
joint effect was HR = 1.86 (95% CI: 1.08–3.19, P = 
2.42×10−2), which was less than the product of the two 
main effects (2.84×3.18 = 9.03). This result indicates an 
antagonistic interaction between low cg14326354PRODH 
methylation and elderly age (HRinteraction = 0.21; 95% 




Figure 2. DNA methylation and age interaction on survival of lung adenocarcinoma (LUAD) patients. (A) Hazard ratio (HR) of 
cg14326354PRODH 5% per decrement of methylation level among different aged patients. The 95% confidence interval (95% CI) 
band of HR for patients aged <57 or >65 years is statistically significant. Top histogram shows distribution of age. (B) Forest 
plots of HR of cg14326354PRODH 5% per decrement of methylation level in young and elderly LUAD patients, categorized based 
on boundary of 95% CI (BoCI) and 1956 United Nations standard. (C) Kaplan-Meier survival curves of low and high methylation 
groups (categorized by median value) among young and elderly LUAD patients defined using BoCI standard. Pheterogeneity was 
used to evaluate heterogeneity of HRs across age groups. 
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Table 1. Joint effect and interaction of low methylation and elderly age on the prognosis of early-stage lung 
adenocarcinoma (LUAD). 
Effect type a Elderly b Low methylation Number Death Crude mortality HR (95% CI) a P a 
 No No 75 17 22.67% Ref. 
 
Main effect 1 No Yes 70 33 47.14% 2.8398 (1.5876,5.0798) 4.35×10-4 
Main effect 2 Yes No 217 98 45.16% 3.1804 (1.8542,5.4553) 2.64×10-5 
Joint effect Yes Yes 222 70 31.53% 1.8590 (1.0840,3.1890) 0.0242 
Interaction c 
  
   0.2058 (0.1070,0.3961) 2.20×10-6 
a Patients categorized into two groups (low vs high) by medium of cg14326354PRODH methylation level. Classification criteria of 
age were based on boundary of 95% confidence interval (CI) standard (young: <57 years; elderly >65 years). 
b Main effects of low methylation and elderly age and their joint effect and interaction were derived from Cox proportional 
hazards model adjusted for covariates. 
c Interaction = Joint effect ÷ (Main effect 1 × Main effect 2). 0.2058 ≈ 1.8590 ÷ (3.1804 × 2.8398). 
 
Further, cis-regulation and genome-wide trans-
regulation analyses were conducted in the TCGA 
cohort. We observed significant correlation between 
cg14326354PRODH and PRODH expression (r = –0.23; P 
= 3.38 × 10-5) in LUAD patients (Figure 3A), indicating 
that cg14326354PRODH cis-regulated gene expression. 
Moreover, genome-wide trans-regulation analysis 
revealed that expression of 821 genes was significantly 
correlated with methylation level of cg14326354PRODH 
(Supplementary Material 3, Figure 3B). KEGG 
enrichment analysis based on 821 trans-regulated genes 
showed several significant immune- or inflammation-
related pathways, such as chemokine signaling, T cell 
receptor and B cell receptor signaling, and cellular 
pathways such as cell differentiation and cell cycle 
(Figure 3C). Notably, these trans-regulated genes were 
also enriched in senescence-related pathways (e.g., 
cellular senescence) and cancer-related pathways (e.g., 
NF-κB signaling).  
 
Because tumor mutational burden (TMB) serves as a 
biomarker to select patients who might benefit from 
immune checkpoint inhibitors [15], we also evaluated 
association between TMB and cg14326354PRODH as 
well as PRODH expression. TMB of each sample is 
shown in Supplementary Material 4. cg14326354PRODH 
was positively correlated with TMB (r = 0.23; P = 
4.04×10-5), while PRODH expression was negatively 
correlated with TMB (r = –0.22; P = 6.62×10-5) 




In this two-stage study using five independent cohorts, 
we systematically investigated methylation–age 
interactions on an epigenome-wide scale. Our results 
show an antagonistic interaction between elderly age 
and low methylation of cg14326354PRODH, indicating 
opportunities for epi-drug intervention due to the 
inherent reversibility of epigenetic events [16] and 
increasing treatment efficiency based on age-specific 
drug targeting. 
 
PRODH is located in chromosome 22q11.2, a region 
often deleted in various human tumors. This gene 
encodes a mitochondrial inner membrane-associated 
enzyme that acts as a tumor suppressor in vitro and in 
vivo [17]. However, PRODH plays a paradoxical role in 
tumors. Hypoxia and nutrient depletion are important 
characteristics of the tumor microenvironment, where 
PRODH may serve as a tumor survival factor [18]. 
Indeed, PRODH supports tumor metastasis formation, 
and inhibiting its activity impairs cancer cell growth, 
indicating PRODH is a potential drug target [19]. A 
metabolic enzyme, PRODH can catabolize proline to 
pyrroline-5-carboxylate (P5C). The process can donate 
electrons that enter the electron transport chain to 
produce reactive oxygen species (ROS), which then 
participate in protective autophagy rather than apoptotic 
cell death [18].  
 
Autophagy, a self-digestion process, plays an important 
role in maintaining intracellular homeostasis. 
Autophagy can clear intracellular abnormally folded 
protein and dysfunctional organelles, inhibit cell stress 
response, and prevent genetic damage in early phases of 
tumorigenesis. However, autophagy helps tumor cells 
survive nutritional deficiencies and hypoxic conditions 
when tumors develop and accumulate more mutations 
to promote malignant progression [20]. Further, tumor-
surrounding normal cells, which are active and essential 
parts of the microenvironment, support tumor 
proliferation by autophagy. Besides, autophagy in 
distant organs may also support growth of tumor tissue 
[21]. Additionally, autophagy can act as a mechanism of 
tumor resistance to chemotherapy agents and lead to 
antagonistic effects of gefitinib combined with cisplatin 
in NSCLC treatment, which may contribute to poor 
therapeutic effectiveness and patient prognosis [22, 23]. 
Further, our results suggest that low methylation of 
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cg14326354PRODH may potentially promote PRODH 
expression, further heighten autophagy to some extent 
[24], and then result in poor prognosis (Figure 4). 
 
Age is an independent risk factor for lung cancer 
survival [25]. Individual aging implies a higher 
abundance of senescent cells in aged tissues and 
reflects an increase in the generation of senescent cells 
[26]. At old age, senescent cells generate a pro-
tumorigenic microenvironment, though at young age 
these cells may protect against transformation into 
primary tumors [27]. A previous study also shows that 
p53 function declines during aging [28] and might 
promote tumor growth and decrease cancer survival 
[29]. Moreover, senescent cells can promote 
reprogramming of tumor stem cells, increase cancer 
stemness, and accelerate tumor growth [30]. Thus, 
combined with our results, increased generation of 
senescent may be relevant to poor NSCLC prognosis 




Figure 3. Scatter plot of cis-regulation, circos plot of genome-wide trans-regulation analysis, and significant pathways of 
gene enrichment pathway analysis. (A) Correlation between DNA methylation of cg14326354PRODH and expression of PRODH. 
The r coefficient and P-value were derived from Pearson correlation analysis. Gene expression was log2-transformed before 
correlation analysis. (B) Circos plot of genome-wide trans-regulation analysis in the TCGA cohort. Blue points ordered by 
genomic position represent P-values of correlation between gene expression and methylation at cg14326354PRODH. Grey lines 
represent significant correlations with Bonferroni-adjusted P ≤ 0.05. (C) KEGG gene enrichment analysis of 821 trans-regulated 
genes correlated with cg14326354PRODH methylation. 
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Autophagy is reduced in aging, likely through several 
mechanisms [31]. Lipofuscin produced during aging 
can destroy the function of lysosomes, restricting 
binding between autophages and lysosomes [32]. In 
addition, expression of lysosome-associated membrane 
glycoprotein (LAMP2a), which assists autophagy, 
decreases during aging and thus can inhibit autophagy 
[33]. Further, by guaranteeing stability of the cellular 
proteome and proper organelle turnover, autophagy can 
prevent or slow down aging and extend lifespan [34]. 
The antagonistic effect exists between aging and the 
autophagy level resulting from low methylation of 
cg14326354PRODH, in spite of the harmful effect of both, 
which could provide a possible mechanism of the 
cg14326354PRODH–age interaction (Figure 4). 
 
The 821 significant trans-regulated genes we identified 
were enriched in KEGG pathways including inflammation 
and immune-related pathways. Notably, cellular 
senescence was involved in these pathways, again 
indicting potential indirect induction of cg14326354PRODH 
on senescence. Meanwhile, the NF-κB pathway, with the 
ability to upregulate genes responsible for inflammation, 
cell survival, proliferation, invasion, angiogenesis, and 
metastasis, often plays a critical role in initiation, 
promotion, progression, and therapy resistance of cancers 
[35, 36]. Further, NF-κB family members can activate or 
inhibit signaling pathways, leading to induction of 
autophagy or transcription of certain pro-autophagic-
regulating genes [35], and can induce senescence [37]. 
Because cell proliferation can be associated with both 
senescence and survival [38, 39], we also analyzed several 
proliferation-associated genes retrieved from the KEGG 
database. Expression of these genes were significantly 
correlated with cg14326354PRODH methylation and 
affected LUAD survival, including MKI67, BTG2, 
KIAA1524, and CDC123 (Supplementary Table 7). Our 
previous study of BTG2 expression and methylation 
already indicated it is a prognostic biomarker of NSCLC 
[7]. These results also indicate the potential role of 
cg14326354PRODH in indirect induction of autophagy, 
senescence, and survival. Further functional studies are 
warranted to elucidate the mechanism of 
cg14326354PRODH and age interaction on LUAD survival. 
 
Age represents a complex surrogate for a host of 
underlying phenomena, although its measurement is 
simple and accurate [40]. A previous study suggested 
that gene–age interactions may partially be surrogates 
for gene–gene and gene–environment interactions 
[41]. In a study investigating the efficacy of 
metronomic vinorelbine to treat patients with 
advanced unresectable NSCLC, age was an important 
factor that decreased treatment efficacy [42]. Our 
study might provide a novel explanation of age effects 
on treatment efficacy from the cg14326354PRODH–age 
interaction perspective. Further clinical studies will 
provide additional insight into cg14326354PRODH and 
its age-specific effects in tumors, which may lead to 
new age-specific biomarkers and therapeutic 





Figure 4. Pathway of DNA methylation–age interaction effect on survival of lung adenocarcinomas (LUAD) patients. 
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Our study has several strengths. First, this is the first 
epigenome-wide study to investigate the interaction 
between DNA methylation and age on NSCLC survival, 
which provides new evidence to account for the missing 
heritability of complex diseases [43] and may further 
reveal the role of age in heterogeneity of NSCLC 
prognosis and treatment efficacy. Second, to identify 
stable and reliable biomarkers, a two-stage study design 
along with Bonferroni correction and sensitivity 
analysis was used to exhaustively search for inter-
actions, which is quite conservative in controlling for 
false positives. Finally, with a large sample size to 
analyze DNA methylation–age interactions, our study 
has improved statistical power to identify complex 
associations with small–medium effect size. 
 
Nonetheless, several limitations also need to be 
acknowledged. First, we did not observe robustly 
significant methylation–age interactions on survival for 
LUSC, which may be due to limited sample size and 
thus insufficient power. However, there was no 
significant heterogeneous effect between LUAD and 
LUSC groups (Supplementary Table 8). Second, the 
association was no longer significant in young LUAD 
patients when the analysis used UN standards to define 
age groups. However, we still observed a significant 
association in patients <57 years old. This effect might 
be because >62% (240/385) of young patients defined 
using the UN standard (57–65 years) attenuated the 
effect of cg14326354PRODH methylation. Therefore, high 
methylation of cg14326354PRODH might benefit survival 
of young LUAD patients. Third, although widespread 
methylation–age interactions may exist, we only 
identified one interaction, which may be due to the most 
conservative correction method used in the discovery 
phase and limited statistical power in the validation 
phase due to low event rate of survival time in the 
TCGA population. We may need longer time to follow-
up early-stage patients in TCGA for their events to 
occur. Nevertheless, the interaction between 
cg14326354PRODH and age was successfully confirmed, 
indicating it was a conservative and robust association. 
Fourth, our analysis was based on the assumption of 
linear additive interaction, and new statistical models 
can be used to properly capture non-linear methylation–
age interactions. Last, the cis-regulation pattern of 
cg14326354PRODH requires more biological evidence, 
although methylation is believed to play a crucial role in 
regulating gene expression [44] and further influence 
disease gene function [45]. Therefore, our findings 
should be interpreted with caution, and functional 
experiments are warranted to confirm these 
associations. 
 
In conclusion, low methylation of cg14326354PRODH 
benefited survival of elderly LUAD patients. Our results 
have implications for not only age-specific prediction of 
cancer survival, but also possible methylation-specific 
drug targeting. 
 
MATERIALS AND METHODS 
 
Lung cancer study populations 
 
Only early-stage (stage I–II) LUAD and LUSC patients 
were included in our study. DNA methylation data was 
harmonized from five cohorts: Harvard, Spain, Norway, 
Sweden, and TCGA. 
 
Harvard 
Since 1992, patients have been recruited at 
Massachusetts General Hospital (MGH) and 
histologically confirmed as primary NSCLC [46]. We 
profiled 151 early-stage patients from this cohort. 
During curative surgery, tumor specimens were 
collected with complete resection and snap-frozen. A 
MGH pathologist evaluated each specimen for tumor 
cell amount (tumor cellularity > 70%) and quality. 
Specimens were classified histologically according to 
World Health Organization (WHO) criteria. The 
Institutional Review Boards at Harvard T.H. Chan 
School of Public Health and MGH approved the study. 
All patients provided written informed consent. 
 
Spain 
The Spain cohort included 226 early-stage NSCLC 
patients recruited from eight sub-centers in 1991–2009 
[47]. Tumor DNA was extracted from fresh-frozen 
tumor specimens and further checked for integrity and 
quantity. Patients provided written consent, and tumors 
were surgically collected. The study was approved by 




 The Norway study population consisted of 133 early-
stage NSCLC patients from Oslo University Hospital-
Riks Hospitalet, Norway, in 2006–2011 [48]. Tumor 
tissues were snap-frozen in liquid nitrogen and stored at 
–80°C until DNA isolation. The project was developed 
with approval of the Oslo University Institutional 
Review Board and Regional Ethics Committee (S-
05307). All patients provided informed consent.  
 
Sweden 
Tumor DNA was collected from 103 early-stage NSCLC 
patients, including 80 LUAD and 23 LUSC patients, at 
the Skane University Hospital in Lund, Sweden [49]. The 
study was developed under the approval of the Regional 
Ethical Review Board in Lund, Sweden (registration no. 
2004/762 and 2008/702). All patients provided written 
informed consent. 
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TCGA 
A total of 332 LUAD and 285 LUSC cases with full 
DNA methylation, survival time, and covariate data 
were included. Level-1 HumanMethylation450 DNA 
methylation data of early-stage NSCLC patient were 
downloaded on October 01, 2015. 
 
Quality control for DNA methylation data 
 
DNA methylation was assessed using Illumina Infinium 
HumanMethylation450 BeadChips (Illumina Inc.). Raw 
image data were imported into Genome Studio 
Methylation ModuleV1.8 (Illumina Inc.) to calculate 
methylation signals and to perform normalization, 
background subtraction, and QC. Unqualified probes 
were excluded if they fit any of the following criteria: 
(i) failed detection (P > 0.05) in ≥5% samples, (ii) 
coefficient of variance (CV) <5%, (iii) all samples 
methylated or all unmethylated, (iv) common single 
nucleotide polymorphisms located in probe sequence or 
in 10-bp flanking regions, (v) cross-reactive probes 
[50], or (vi) data did not pass QC in all cohorts. 
Samples with >5% undetectable probes were excluded. 
Methylation signals were further processed for quantile 
normalization (betaqn function in R package minfi 
[51]), type I and II probe correction (BMIQ function in 
R package lumi [52]), and adjusted for batch effects 
(ComBat function in R package sva) [53]. Details of QC 
process are described Supplementary Figure 6. 
 
Quality control for gene expression data 
 
The TCGA workgroup completed mRNA sequencing 
data processing and QC. Raw counts were normalized 
using RNA-sequencing by expectation maximization 
(RSEM). Level-3 gene quantification data were 
downloaded from the TCGA data portal and were 
further checked for quality. Expression of genes was 
extracted and log2-transformed before analysis. 
Normalization results were then evaluated through 
boxplots of the distribution of gene expression across all 




Statistical analysis flow is presented in Figure 1. 
Patients from Harvard, Spain, Norway, and Sweden 
study cohorts were assigned to the discovery phase, 
while patients in TCGA were assigned to the validation 
phase.  
 
In the discovery phase, histology-stratified analysis and 
Cox proportional hazards model adjusted for age, 
smoking status, sex, clinical stage, and study center 
were applied to test the methylation–age interaction 
effect on overall survival in LUAD and LUSC patients 
using the R package survival [54]. Hazard ratio (HR) 
and 95% confidence interval (CI) were described per 
5% level of methylation decrement. The P-value 
threshold for multiple testing was established using the 
Bonferroni method, which set the significance level to 
0.05 divided by number of tests. This way, overall type 
I error was controlled at the 0.05 level. In our study, 
significance level of interaction analysis was defined as 
1.60×10-07 = 0.05/311,891. Interactions with P ≤ 
1.60×10-07 were screened out and then further 
confirmed in the validation phase. Robustly significant 
probes were retained if they fit both of the following 
criteria: (i) interaction P ≤ 0.05, and (ii) direction of 
interaction effects was consistent across both phases. In 
sensitivity analysis, patients were excluded if their 
methylation values were out of range mean ± 
3×standard deviation (SD) on logit2-transformed scale. 
Genome-wide expression correlation analysis was 
performed to identify potential trans-regulation genes in 
TCGA. KEGG enrichment analysis of potential trans-
regulation genes (Bonferroni adjusted P < 0.05) was 
conducted using R package clusterProfiler [55].  
 
Continuous variables were summarized as mean ± SD; 
categorical variables were described as n (%). Kaplan-
Meier survival curves were used to illustrate survival 
difference between patients in low and high methylation 
groups (categorized by median value). We used two 
classification criteria to define young and elderly 
patients: (i) the UN standard (1956) of 65 years old as 
the cut-off value to distinguish elderly and young 
people [56], (ii) and a cut-off value calculated based on 
BoCI of HR of the CpG probe. All statistical analyses 




NSCLC: non-small cell lung cancer; LUSC: lung 
squamous cell carcinoma; LUAD: lung 
adenocarcinoma; TCGA: The Cancer Genome Atlas; 
BoCI: boundary of 95% CI; UN: United Nations; QC: 
quality control; HR: hazard ratio; CI: confidence 
interval; SD: standard deviation; PRODH: proline 
dehydrogenase. 
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Supplementary Figure 1. Manhattan plot of methylation–age interaction P-values derived from Cox proportional hazards 
model adjusted for age, smoking status, sex, clinical stage, and study cohort in lung adenocarcinoma (LUAD) patients in the 
discovery phase. Red line represents Bonferroni adjusted P ≤ 0.05. Blue dot represents one CpG probe identified in this study, with 






Supplementary Figure 2. Association results of lung adenocarcinoma (LUAD)-specific cg14326354 PRODH–age interaction using 
leave-one-out method for validation. Size of each box represents the sample size of each cohort. Hazard ratio (HR) of cg14326354PRODH 
5% per decrement of methylation level and P-value of interaction term derived from the Cox proportional hazards model adjusted for age, 
smoking status, sex, clinical stage, and study cohort in LUAD patients when leaving one cohort out. 
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Supplementary Figure 3. Meta-analysis of interaction between DNA methylation of cg14326354PRODH and age for lung 
adenocarcinoma (LUAD) patients from five cohorts. Fixed effect and random effect models were both applied, and effect 
heterogeneity among five cohorts was tested. Size of each box represents the sample size of each cohort, and diamond represents the overall 
effect of cg14326354PRODH in five cohorts. Hazard ratio (HR) of cg14326354PRODH 5% per decrement of methylation level and P-value of 
interaction term derived from the Cox proportional hazards model adjusted for age, smoking status, sex, clinical stage, and study cohort in 





Supplementary Figure 4. Association results of the cg14326354PRODH effect on lung adenocarcinoma (LUAD) survival in 
different age subgroups. Size of each box represents the sample size of each cohort. Hazard ratio (HR) of cg14326354PRODH 5% per 
decrement of methylation level and P-value derived from the Cox proportional hazards model adjusted for age, smoking status, sex, clinical 
stage, and study cohort in LUAD patients in each age subgroup. 
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Supplementary Figure 5. Results of correlation analysis between tumor mutational burden (TMB) and PRODH methylation 
as well as expression. Correlation coefficient (r) and P-value were derived from Pearson correlation analysis. TMB as well as gene 




Supplementary Figure 6. Quality control procedures for epigenome-wide DNA methylation data.  
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Supplementary Tables 
 
Supplementary Table 1. Demographic and clinical characteristics for early-stage non-small cell lung cancer (NSCLC) 









(N = 151) 
Cohort 2: 
Spaina 
(N = 226) 
Cohort 3: 
Norway 
(N = 133) 
Cohort 4: 
Sweden 
(N = 103) 
Discovery: 
All 
(N = 613) 
Cohort 5: 
TCGA 
(N = 617) 
Overall 
samples 
(N = 1230) 




Sex, n (%) 
  
    
 
Female 67 (44.37) 105 (46.46) 71 (53.38) 54 (52.43) 297 (48.45) 255 (41.33) 552 (44.88) 
Male 84 (55.63) 121 (53.54) 62 (46.62) 49 (47.57) 316 (51.55) 362 (58.67) 678 (55.12) 
Smoking status,  
n (%)   
     
Never 18 (11.92) 30 (13.57) 17 (12.78) 18 (17.48) 83 (13.65) 55 (9.18) 138(11.22) 
Former 81 (53.64) 120 (54.30) 74 (55.64) 54 (52.43) 329 (54.11) 376 (62.77) 705 (58.41) 
Current 52 (34.44) 71 (32.13) 42 (31.58) 31 (30.10) 196 (32.24) 168 (28.05) 364 (30.16) 
Unknown 0 5 0 0 5 18 23 
Clinical stage, n (%) 
  
    
 
I 104 (68.87) 183 (80.97) 93 (69.92) 95 (92.23) 475 (77.49) 393 (63.70) 868 (70.57) 
II 47 (31.13) 43 (19.03) 40 (30.08) 8 (7.77) 138 (22.51) 224 (36.30) 362 (29.43) 
Histology, n (%) 
  
    
 
LUAD 96 (63.58) 183 (80.97) 133 (100.00) 80 (77.67) 492 (80.26) 332 (53.81) 824 (66.99) 
LUSC 55 (36.42) 43 (19.03) 0 (0.00) 23 (22.33) 121 (19.74) 285 (46.19) 406 (33.01) 
Chemotherapy, n (%) 
  
    
 
No 142 (94.04) 177 (90.77) 102 (76.69) 67 (90.54) 488 (88.25) 194 (76.98) 682 (84.72) 
Yes 9 (5.96) 18 (9.23) 31 (23.31) 7 (9.46) 65 (11.75) 58 (23.02) 123 (15.28) 
Unknown 0 31 0 29 60 365 425 
Radiotherapy, n (%) 
  
    
 
No 132 (87.42) 184 (94.36) 132 (99.25) 
74 
(100.00) 
522 (94.39) 239 (94.84) 761 (94.53) 
Yes 19 (12.58) 11 (5.64) 1 (0.75) 0 (0.00) 31 (5.61) 13 (5.16) 44 (5.47) 
Unknown 0 31 0 29 60 365 425 
Adjuvant therapyb, n 
(%)   
    
 
No 127 (84.11) 168 (86.15) 101 (75.94) 67 (90.54) 463 (83.73) 187 (74.21) 650 (80.75) 
Yes 24 (15.89) 27 (13.85) 32 (24.06) 7 (9.46) 90 (16.27) 65 (25.79) 155 (19.25) 
Unknown 0 31 0 29 60 365 425 
Survival year 
  
    
 















Dead (%) 122 (80.79) 101 (44.69) 42 (31.58) 58 (31.58) 323 (52.69) 142 (23.01) 465 (37.80) 
aCohort 2: Spain is a collaborative cohort, recruiting samples from Spain, Italy, UK, France, and USA.  
bAdjuvant therapy includes chemotherapy or radiotherapy. 
*Restricted mean survival time is given since median is not available. 
LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma 
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Supplementary Table 2. Results for two lung adenocarcinoma (LUAD)-specific methylation–age interactions 
identified from a two-stage epigenome-wide association study. 
Variable 
Discovery phase Validation phase Combined data 
HR 95% CI P HR 95% CI P HR 95% CI P 
cg14326354 2.986 1.921 4.640 1.16×10-06 3.442 1.146 10.337 2.76×10-02 1.885 1.429 2.487 7.16×10-06 
Age 0.860 0.809 0.915 1.74×10-06 0.854 0.728 1.002 5.36×10-02 0.926 0.890 0.964 1.53×10-04 
Interaction 0.982 0.976 0.989 1.11×10-07 0.981 0.966 0.997 2.02×10-02 0.989 0.986 0.994 9.18×10-07 
cg08700284 62.927 15.807 250.507 4.20×10-09 3.336 0.024 455.52 6.31×10-01 8.960 3.779 21.243 7.16×10-06 
Age 0.349 0.237 0.513 9.31×10-08 0.718 0.175 2.947 6.46×10-01 0.591 0.466 0.751 1.62×10-05 
Interaction 0.944 0.925 0.964 6.55×10-08 0.981 0.910 1.057 6.17×10-01 0.971 0.959 0.984 9.18×10-07 
HR: hazard ratio; 95% CI: 95% confidence interval 
 
Supplementary Table 3. Annotation information for significant lung adenocarcinoma (LUAD)-specific CpG probe. 
CpG probe CHR BP Region 
Relation to CpG 
islands 
Gene descriptiona 
cg14326354 22 18900453 3'UTR S_Shelf 
proline dehydrogenase 1 
(PRODH) 
aHyperlinks provide literature-based evidence for each gene from DAVID (https://david.ncifcrf.gov). 
CHR: chromosome; BP: basepair 
 
Supplementary Table 4. Results of interaction for sensitivity analysis of one significant lung adenocarcinoma (LUAD)-
specific CpG probe. 
Variable 
Discovery phase Validation phase Combined data 
HR 95% CI P HR 95% CI P HR 95% CI P 
cg14326354 3.056 1.950 4.792 1.11×10-06 3.522 1.156 10.73 2.67×10-02 3.048 2.043 4.547 4.77×10-08 
Age 0.858 0.806 0.914 1.61×10-06 0.853 0.726 1.003 5.36×10-02 0.861 0.814 0.911 1.80×10-07 
Interaction 0.982 0.976 0.989 1.03×10-07 0.981 0.966 0.997 2.09×10-02 0.982 0.976 0.988 3.18×10-09 
In sensitivity analysis, patients were excluded if their methylation values were out of range mean± 3×standard deviation on 
logit2 transformed scale.  
HR: hazard ratio; 95% CI: 95% confidence interval 
 
Supplementary Table 5. Results of heterogeneity test of the interaction effect between subgroups categorized by 
covariates. 
Covariate Subgroup HRinteraction 95% CI Pinteraction Qheterogeneity Pheterogeneity 
Never or former smoker 0.982 0.974 0.989 8.42×10-7 
Current smoker 0.982 0.971 0.992 7.85×10-4 
Male 0.983 0.974 0.990 1.57×10-5 
Female 0.978 0.968 0.988 2.10×10-5 
I 0.985 0.978 0.992 9.56×10-5 
II 0.977 0.965 0.988 1.65×10-4 
Harvard 0.979 0.964 0.995 7.92×10-3 
Norway 0.987 0.968 1.006 1.72×10-1 
Spain 0.985 0.973 0.997 1.75×10-2 
Sweden 0.983 0.959 1.008 1.77×10-1 
TCGA 0.981 0.966 0.997 2.02×10-2 
HR: hazard ratio; 95% CI: 95% confidence interval 
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Supplementary Table 6. Results of low cg14326354PRODH methylation effect on lung adenocarcinoma (LUAD) survival 
in young and elderly populations defined using boundary of 95% confidence interval (BoCl) standard. 
Population 
Discovery phase Validation phase Combined data 
HR 95% CI P HR 95% CI P HR 95% CI P 
Young (age <57 years) 1.182 1.005 1.389 4.29×10-2 1.294 1.023 1.636 3.18×10-2 1.200 1.030 1.401 1.97×10-2 
Elderly (age >65 years) 0.810 0.742 0.885 3.12×10-6 0.858 0.754 0.976 1.99×10-2 0.814 0.751 0.882 5.38×10-7 
Patients from Harvard, Spain, Norway, and Sweden cohorts were assigned to discovery phase; patients in TCGA were 
assigned to validation phase. 
HR: hazard ratio; 95% CI: 95% confidence interval 
 
Supplementary Table 7. Correlation analysis of association between cg14326354PRODH methylation and proliferation-
associated gene expression in lung adenocarcinoma (LUAD) patients using The Cancer Genome Atlas data, as well as 
survival analysis of proliferation-associated genes (from KEGG database). 
Correlation coefficient (r), 95% CI, and P-values were derived from Pearson correlation analysis; survival analysis HR, 95% CI, 
and P-values were derived from Cox proportional hazards model. 
HR: hazard ratio; 95% CI: 95% confidence interval. 
 
Supplementary Table 8. Results of heterogeneity test of the interaction effect between lung adenocarcinoma (LUAD) 
and lung squamous cell carcinoma (LUSC) populations. 
CpG probe 
LUAD LUSC Heterogeneity 
HR 95% CI HR 95% CI Q P 
cg08470135 0.944  0.925  0.964  0.975 0.946 1.004 2.97 0.0847 
cg14326354 0.982  0.976  0.989  0.982 0.969 0.995 0.00 0.9764 
HR: hazard ratio; 95% CI: 95% confidence interval. 
  
Gene 
Correlation analysis Survival analysis 
r 95% CI P HR 95% CI P 
BTG2 -0.313 -0.408 -0.212 6.80×10-09 0.704 0.564 0.878 1.83×10-03 
NPDC1 -0.266 -0.364 -0.163 9.88×10-07 0.937 0.755 1.164 0.558 
KIAA1524 0.243 0.139 0.342 8.40×10-06 1.383 1.103 1.733 4.94×10-03 
MKI67 0.199 0.093 0.301 2.84×10-04 1.440 1.115 1.859 5.14×10-03 
BTG1 -0.188 -0.290 -0.081 6.29×10-04 1.257 0.869 1.819 0.225 
BOP1 0.122 0.014 0.227 2.72×10-02 1.170 0.910 1.505 0.222 
BTG4 -0.118 -0.223 -0.010 3.29×10-02 0.995 0.769 1.288 0.971 
CDC123 0.111 0.003 0.217 4.46×10-02 1.798 1.045 3.097 3.41×10-02 
PA2G4 0.091 -0.017 0.197 9.94×10-02     
MTCP1NB 0.079 -0.030 0.185 1.55×10-01     
C8orf22 -0.067 -0.174 0.042 2.29×10-01     
HEY1 0.061 -0.048 0.168 2.71×10-01     
PPDPF -0.058 -0.166 0.050 2.92×10-01     
SIPA1L2 0.055 -0.054 0.162 3.24×10-01     
MTCP1 0.047 -0.061 0.155 3.94×10-01     
SIPA1L3 -0.039 -0.146 0.070 4.84×10-01     
URGCP 0.036 -0.073 0.144 5.17×10-01     
SAV1 -0.032 -0.139 0.077 5.69×10-01     
BTG3 -0.024 -0.132 0.084 6.63×10-01     
PDS5B -0.023 -0.131 0.085 6.74×10-01     
SIPA1 -0.008 -0.117 0.100 8.80×10-01     
PEA15 -0.006 -0.114  0.103  9.20×10-01     
SIPA1L1 0.000 -0.108  0.108  9.99×10-01     
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Supplementary Materials 
 
Please browse Full Text version to see the data of Supplementary Materials 1 to 4. 
 
 
Supplementary Material 1. Epigenome-wide association results in LUAD patients. Only summary results of 
interaction terms were shown in the table. 
 
Supplementary Material 2. Epigenome-wide association results in LUSC patients. Only summary results of 
interaction terms were shown in the table. 
 
Supplementary Material 3. Results of genome-wide trans-regulation analysis of cg14326354 methylation using gene 
expression data and DNA methylation data from TCGA. 
 
Supplementary Material 4. Results of Tumor mutational burden (TMB) analysis of each sample from TCGA. 
